Active Recombinant Human CX3CL1 Protein (315 aa)

• Cat.No.: CX3CL1-283C
• Product Overview: Recombinant Human Fractalkine/CX3CL1 produced in CHO cells is a polypeptide chain containing 315 amino acids. A fully biologically active molecule, rhFractalkine/CX3CL1 has a molecular mass of 50-75 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques.

Specification

• Description: Chemokine (C-X3-C motif) ligand 1 (CX3CL1) is a known member of the CX3C chemokine family. It is also commonly known under the names fractalkine (in humans) and neurotactin (in mice). The polypeptide structure of CXC3L1 differs from the typical structure of other chemokines. For example, the spacing of the characteristic N-terminal cysteines is different; there are three amino acids separating the initial pair of cysteines in CX3CL1, while there are none in CC chemokines and only one in CXC chemokines. CX3CL1 is produced as a long protein (with 373-amino acid in humans) with an extended mucin-like stalk and a chemokine domain on top. The mucin-like stalk allows it to bind to the surface of certain cells. Soluble CX3CL1 potently chemoattracts T cells and monocytes, while the cell-bound chemokine promotes strong adhesion of leukocytes to activated endothelial cells, where it is primarily expressed. CX3CL1 can signal through the chemokine receptor CX3CR1.
• Source: CHO
• Species: Human
• Form: Sterile Filtered White lyophilized (freeze-dried) powder.
• Bio-activity: The EC50 value of Human Fractalkine/CX3CL1 on Ca^2+ mobilization assay in CHO-K1/Gα15/hCX3CR1 cells (human Gα15 and hCX3CR1 stably expressed in CHO-K1 cells) is less than 1.5 μg/mL.
• Molecular Mass: 50-75 kDa, observed by reducing SDS-PAGE.
• Protein length: 315
• AA Sequence: QHHGVTKCNITCSKMTSKIPVALLI HYQQNQASCGKRAIILETRQHRLFC ADPKEQWVKDAMQHLDRQAAALTRN GGTFEKQIGEVKPRTTPAAGGMDES VVLEPEATGESSSLEPTPSSQEAQR ALGTSPELPTGVTGSSGTRLPPTPK AQDGGPVGTELFRVPPVSTAATWQN SAPHQPGPSLWAEAKTSEAPSTQDP STQASTASSPAPEENAPSEGQRVWG QGQSPRPENSLEREEMGPVPAHTDA FQDWGPGSMAHVSVVPVSSEGTPSR EPVASGSWTPKAEEPIHATMDPQRL GVLITPVPDAQAATR
• Endotoxin: < 0.2 EU/μg, determined by LAL method.
• Purity: > 95% as analyzed by SDS-PAGE.
• Storage: Lyophilized recombinant Human Fractalkine/CX3CL1 remains stable up to 6 months at -80 centigrade from date of receipt. Upon reconstitution, Human Fractalkine/CX3CL1 should be stable up to 1 week at 4 centigrade or up to 3 months at -20 centigrade.
• Storage Buffer: Lyophilized after extensive dialysis against PBS.
• Reconstitution: Reconstituted in ddH2O or PBS at 100 μg/mL.

Gene Information

• Gene Name: CX3CL1 chemokine (C-X3-C motif) ligand 1 [ Homo sapiens ]
• Official Symbol: CX3CL1
• Synonyms: CX3CL1; chemokine (C-X3-C motif) ligand 1; SCYD1, small inducible cytokine subfamily D (Cys X3 Cys), member 1 (fractalkine, neurotactin); fractalkine; ABCD 3; C3Xkine; CXC3; CXC3C; neurotactin; NTN; C-X3-C motif chemokine 1; small-inducible cytokine D1; CX3C membrane-anchored chemokine; small inducible cytokine subfamily D (Cys-X3-Cys), member-1; small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine, neurotactin); NTT; SCYD1; ABCD-3
• Gene ID: 6376
• mRNA Refseq: NM_002996
• Protein Refseq: NP_002987
• MIM: 601880
• UniProt ID: P78423

Reviews

03/15/2022

the CX3CL1 protein's compatibility with various experimental techniques further supports its usability.

08/06/2021

One of the standout features of the CX3CL1 protein is the excellent technical support provided by the manufacturer.

06/03/2021

Whether I need to study protein-protein interactions, protein localization, or protein folding, the CX3CL1 protein consistently delivers precise and meaningful data.

Q&As

In what ways is CX3CL1 linked to the modulation of pain perception and neuropathic pain conditions?

CX3CL1 is involved in pain modulation, and its dysregulation is associated with neuropathic pain conditions. Understanding its role may lead to the development of novel analgesic therapies.

Are there any ongoing clinical trials targeting CX3CL1 for therapeutic purposes?

Yes, several clinical trials are investigating the therapeutic potential of targeting CX3CL1 in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

In cardiovascular diseases, how does CX3CL1 impact inflammation and vascular function?

CX3CL1 contributes to inflammation in cardiovascular diseases and affects vascular function. Studying its role helps in understanding the pathophysiology of conditions like atherosclerosis.

How does CX3CL1 influence the recruitment and activation of immune cells in the context of inflammation?

CX3CL1 acts as a chemoattractant, facilitating the recruitment and activation of immune cells at the site of inflammation, playing a pivotal role in immune response regulation.

How is CX3CL1 being investigated for its potential as a biomarker in various diseases?

Researchers are exploring CX3CL1 as a potential biomarker for diseases such as rheumatoid arthritis and certain cancers, aiming to develop diagnostic tools and monitor disease progression.